MTOR and neoplasm: Studies on preclinical models of panNETs (e.g., RIP1-Tag2 oncomice) showed that activating alterations of mTOR were specific of tumor cells, when compared to normal tissue, and that treatment with rapamycin reduced proliferation and increased apoptosis.